Journal
ACS MEDICINAL CHEMISTRY LETTERS
Volume 6, Issue 5, Pages 491-495Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsmedchemlett.5b00037
Keywords
Methyltransferase; PRC2; EZH2; B cell lymphoma; KARPAS-422; xenograft; in vivo chemical probe
Categories
Ask authors/readers for more resources
Inhibitors of the protein methyltransferase Enhancer of Zeste Homolog 2 (EZH2) may have significant therapeutic potential for the treatment of B cell lymphomas and other cancer indications. The ability of the scientific community to explore fully the spectrum of EZH2-associated pathobiology has been hampered by the lack of in vivo-active tool compounds for this enzyme. Here we report the discovery and characterization of EPZ011989, a potent, selective, orally bioavailable inhibitor of EZH2 with useful pharmacokinetic properties. EPZ011989 demonstrates significant tumor growth inhibition in a mouse xenograft model of human B cell lymphoma. Hence, this compound represents a powerful tool for the expanded exploration of EZH2 activity in biology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available